Business Context and Reporting Period
Company: Denali Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 9, 2025
Event: Entry into a Material Definitive Agreement for a public offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Offering Structure: Public offering of 9,142,857 shares of Common Stock ("Firm Shares") and pre-funded warrants to purchase 2,285,714 shares.
- Public Offering Price: $17.50 per share for Common Stock; $17.49 per underlying share for Pre-Funded Warrants.
- Underwriting Price: $16.625 per share for Common Stock; $16.615 per underlying share for Pre-Funded Warrants.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 1,714,285 shares.
- Expected Gross Proceeds: Approximately $200 million, or $230 million if the over-allotment option is exercised in full (before deducting discounts and expenses).
- Expected Closing Date: December 11, 2025.
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics. These figures are not applicable to this specific transaction report.
Material Changes Versus Prior Period
This filing represents a discrete capital event and does not report comparative operational performance against a prior period. The primary material change is the anticipated increase in cash liquidity upon the closing of the offering and the dilution of existing shareholders due to the issuance of new shares and warrants.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: The offering is expected to close on December 11, 2025, subject to customary closing conditions.
- Risks and Contingencies: The filing includes forward-looking statements regarding the timing and completion of the offering. Actual results may differ due to market conditions or failure to satisfy closing conditions.
- Warrant Restrictions: Holders of Pre-Funded Warrants are restricted from exercising if it would result in beneficial ownership exceeding 4.99% of outstanding shares, unless they provide 61 days' prior notice to increase this limit to 19.99%.
- Unusual Items: None reported beyond the standard terms of the underwriting agreement.
Important Facts for Investor Verification
- Verify the final closing date and whether the underwriters exercised the over-allotment option to purchase the additional 1,714,285 shares.
- Confirm the net proceeds after deducting underwriting discounts, commissions, and offering expenses.
- Review the Company's most recent Form 10-Q (filed November 6, 2025) and Form 10-K (filed February 27, 2025) for current cash position and burn rate to assess the impact of the new capital.
- Check for any subsequent filings regarding the use of proceeds or changes in the offering terms.